Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company that engages in the psychiatry drug development business. The company develops ALTO-100 for the treatment of patients with major depressive disorder (MDD) and po...
Q1 2026
May 13, 2026
FY 2025
Mar 16, 2026
Q4 2025
Q3 2025
Nov 12, 2025
Q2 2025
Aug 13, 2025